首页> The Lancet. Microbe> Efficacy, immunogenicity, and safety of the live attenuated nasal pertussis vaccine, BPZE1, in the UK: a randomised, placebo-controlled, phase 2b trial using a controlled human infection model with virulent Bordetella pertussis.

Efficacy, immunogenicity, and safety of the live attenuated nasal pertussis vaccine, BPZE1, in the UK: a randomised, placebo-controlled, phase 2b trial using a controlled human infection model with virulent Bordetella pertussis.

导出 LinkOut

翻译打印收藏纠错

第一作者： Diane,Gbesemete

第一单位： NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Controlled Human Infection Group, School of Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.

作者： Diane,Gbesemete ^[1] ; Maheshi N,Ramasamy ^[2] ; Muktar,Ibrahim ^[3] ; Alison R,Hill ^[1] ; Lucy,Raud ^[1] ; Daniela M,Ferreira ^[2] ; Jonathan,Guy ^[1] ; Adam P,Dale ^[1] ; Jay R,Laver ^[1] ; Tyween,Coutinho ^[1] ; Saul N,Faust ^[4] ; Thomas A N,Reed ^[5] ; Gavin,Babbage ^[5] ; Lisa,Weissfeld ^[6] ; Wei,Lang ^[6] ; Camille,Locht ^[7] ; Vivek,Samal ^[8] ; Peter,Goldstein ^[8] ; Ken,Solovay ^[8] ; Keith,Rubin ^[8] ; Stephanie,Noviello ^[8] ; Robert C,Read ^[1]

作者单位： NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Controlled Human Infection Group, School of Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK. ^[1] Oxford Vaccine Group, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. ^[2] NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Controlled Human Infection Group, School of Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK; Department of Infection, University Hospital Southampton NHS Foundation Trust, Southampton, UK. ^[3] NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Science, University of Southampton, Southampton, UK. ^[4] NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK. ^[5] WCG Clinical, Princeton, NJ, USA. ^[6] Institut Pasteur de Lille, Inserm U1019, CNRS UMR9017, Centre for Infection and Immunity of Lille, CHU Lille, Inserm, University of Lille, Lille, France. Electronic address: camille.locht@pasteur-lille.fr. ^[7] ILiAD Biotechnologies, Weston, FL, USA. ^[8]

医学主题词青少年(Adolescent);成年人(Adult);女(雌)性(Female);人类(Humans);男(雄)性(Male);中年人(Middle Aged);青年人(Young Adult);投药, 鼻内(Administration, Intranasal);抗体, 细菌(Antibodies, Bacterial);百日咳博德特菌(Bordetella pertussis);百日咳菌苗(Pertussis Vaccine);疫苗, 减毒(Vaccines, Attenuated);百日咳(Whooping Cough)

DOI 10.1016/j.lanmic.2025.101211

PMID 41344352

发布时间 2026-01-08

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

The Lancet. Microbe

2025年6卷12期

101211页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

The Lancet. Microbe

2025年6卷12期

101211页

检索历史清除

Efficacy, immunogenicity, and safety of the live attenuated nasal pertussis vaccine, BPZE1, in the UK: a randomised, placebo-controlled, phase 2b trial using a controlled human infection model with virulent Bordetella pertussis.

The Lancet. Microbe

相似文献

同项目论文

The Lancet. Microbe

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Efficacy, immunogenicity, and safety of the live attenuated nasal pertussis vaccine, BPZE1, in the UK: a randomised, placebo-controlled, phase 2b trial using a controlled human infection model with virulent Bordetella pertussis.

The Lancet. Microbe

相似文献

同项目论文

The Lancet. Microbe

相关期刊

检索历史清除